<< Back
AquaBounty Technologies, Inc. Results for the quarter ended March 31, 2018

MAYNARD, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- AquaBounty Technologies, Inc. (NASDAQ:AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NYSE:XON), announces the Company’s financial results for the quarter ended March 31, 2018.

Financial and Operational Summary:

  • Completed public offering of common shares and warrants, raising net funds of $10.6 million;
  • received approval from the U.S. Food and Drug Administration (“FDA”) to raise AquAdvantage® Salmon at the Indiana facility;
  • net loss for the three-month period ended March 31, 2018, increased to $2.4 million from $2.1 million in the corresponding period of the previous year, reflecting pre-production costs at the Indiana farm site and commencement of R&D activities at the Rollo Bay hatchery; and
  • cash and cash equivalents were $6.9 million (December 31, 2017: $0.5 million).

AquaBounty previously announced that it had received FDA approval to raise AquAdvantage Salmon at its land-based contained facility near Albany, Indiana.  However, the Company is currently prevented from importing its AquAdvantage Salmon eggs for the facility from Canada due to the existence of an “Import Alert” pending the FDA’s issuance of final labelling guidance for the product.  The Company is fully prepared to comply with labelling requirements and hopes that this process will conclude in the near term.

Ronald Stotish, Chief Executive Officer of AquaBounty, stated: “In this quarter, we achieved our two main objectives of completing our public offering and receiving FDA approval for our Indiana farm site facility. We anticipate stocking the tanks in the coming months.”

About AquAdvantage Salmon – AquAdvantage Salmon is an Atlantic salmon that has been bioengineered to grow to market size in about half the time of a traditional farmed Atlantic salmon. It improves the economics of producing salmon in land-based contained facilities. AquAdvantage Salmon is a healthy, environmentally sustainable alternative to imported farmed Atlantic salmon.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding the potential for and possible timing of the FDA’s issuance of final labeling guidance, the lifting of the Import Alert, the stocking of the Indiana farm site facility with eggs, and the raising of AquAdvantage® Salmon at that facility. Forward-looking statements may be identified with words such as “will,” “may,” “expect,” “plan,” “anticipate,” “upcoming,” “believe,” “estimate,” or similar terminology, and the negative of these terms. Forward-looking statements are not promises or guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements. For additional information regarding these and other risks faced by us, please refer to our public filings with the Securities and Exchange Commission (“SEC”), available on the Investors section of our website at www.aquabounty.com and on the SEC’s website at www.sec.gov.


AquaBounty Technologies, Inc.
Consolidated Balance Sheets
(Unaudited)

  As of
  March 31, December 31,
    2018     2017  
Assets    
Current assets:    
Cash and cash equivalents $   6,839,389   $    492,861  
Certificate of deposit   13,045     13,422  
Other receivables   217,536     183,926  
Inventory   125,293     172,363  
Prepaid expenses and other current assets   156,973     527,322  
Total current assets   7,352,236     1,389,894  
     
Property, plant and equipment, net   23,599,868     21,802,976  
Definite-lived intangible assets, net   181,569     184,995  
Indefinite-lived intangible assets   191,800     191,800  
Other assets   162,093     162,093  
Total assets $   31,487,566   $   23,731,758  
     
Liabilities and stockholders’ equity    
Current liabilities:    
Accounts payable and accrued liabilities $   2,092,927   $   2,666,855  
Current debt   59,260     49,794  
Total current liabilities   2,152,187     2,716,649  
     
Long-term debt   3,001,813     3,034,420  
Total liabilities   5,154,000     5,751,069  
     
Commitments and contingencies    
     
Stockholders’ equity:    
Common stock, $0.001 par value, 200,000,000 shares authorized;  
12,675,533 (2017: 8,895,094) shares outstanding   12,676     8,895  
Additional paid-in capital   137,629,187     126,718,186  
Accumulated other comprehensive loss   (326,002 )   (213,884 )
Accumulated deficit   (110,982,295 )   (108,532,508 )
Total stockholders’ equity   26,333,566     17,980,689  
     
Total liabilities and stockholders’ equity $   31,487,566   $   23,731,758  
             


AquaBounty Technologies, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)

  Three Months Ended
  March 31,
    2018     2017  
Revenues    
Product revenues $   19,097   $    -  
     
Costs and expenses    
Product costs   16,232     -  
Sales and marketing   81,647     208,288  
Research and development   977,817     720,022  
General and administrative   1,386,873     1,120,788  
Total costs and expenses   2,462,569     2,049,098  
     
Operating loss   (2,443,472 )   (2,049,098 )
     
Other income (expense)    
Gain on disposal of equipment   1,160     -  
Interest expense   (5,402 )   (5,280 )
Other income (expense), net   (2,073 )   (1,365 )
Total other income (expense)   (6,315 )   (6,645 )
     
Net loss $  (2,449,787 ) $  (2,055,743 )
     
Other comprehensive loss:    
Foreign currency translation loss   (112,118 )   (14,286 )
Total other comprehensive loss   (112,118 )   (14,286 )
     
Comprehensive loss $    (2,561,905 ) $  (2,070,029 )
     
     
Basic and diluted net loss per share $    (0.21 ) $    (0.24 )
Weighted average number of common shares -    
basic and diluted   11,940,874     8,400,795  
For further information, please contact:

Dave Conley, Director of Communications
AquaBounty Technologies, Inc.
613 294 3078

Primary Logo

Source: AquaBounty Technologies, Inc.